Amneal Pharmaceuticals, Inc.
AMRXNasdaqHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B |
| Operating income | $394.1M | $249.3M | $204.4M | −$94.9M | $152.7M | $91.2M |
| Net income | $72.1M | −$116.9M | −$84.0M | −$270.6M | $13.2M | $67.8M |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$70.8M | −$109.3M | $19.8M | $298.4M | $360.3M | $303.3M |
| EPS (diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 |
| Shares out. | 310.0M | 307.0M | 176.1M | 150.9M | 151.8M | 148.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 13.1%
- Net margin
- 2.4%
- Return on equity
- −101.8%
- Return on assets
- 2.0%
- Return on capital (ROCE)
- 14.1%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-0.23
- Revenue growth (YoY)
- 8.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −7.3%clean
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 good- Negative shareholder equity
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- TRETINOINMay 14, 2026
- SERTRALINE HYDROCHLORIDEJan 28, 2026
- ELTROMBOPAG OLAMINEJan 14, 2026
- SODIUM BICARBONATEJan 13, 2026
- PHYTONADIONENov 4, 2025
- EPINEPHRINEOct 14, 2025
- LABETALOL HYDROCHLORIDEOct 2, 2025
- CALCITONIN-SALMONSep 26, 2025
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2022-12Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Phase 1Recruitingreadout ~2025-03-01A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 8.0M | 5.4 | -30.8% |
| Apr 30, 2026 | 11.5M | 6.5 | +34.5% |
| Apr 15, 2026 | 8.6M | 6.1 | +18.9% |
| Mar 31, 2026 | 7.2M | 3.4 | -33.6% |
| Mar 13, 2026 | 10.8M | 4.5 | +9.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 7, 2026
- Results of operationsMay 7, 2026
- Entered a material agreement · Results of operations · Unregistered equity sale · Regulation FD disclosureApr 22, 2026
- Results of operations · Regulation FD disclosureFeb 27, 2026
- Entered a material agreement · New financial obligationFeb 3, 2026
- Other material eventJan 28, 2026
- Results of operations · Regulation FD disclosureJan 13, 2026
- Results of operations · Regulation FD disclosureOct 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.